IGF-1 LR3 Spray (1MG)

IGF-1 LR3 in pre-reconstituted intranasal spray format — the same Long-R3 IGF-1 reference peptide as our 1mg lyophilized standard, supplied in a metered-dose vial for laboratory protocols where on-site reconstitution is impractical.

Format rationale

Intranasal-format references reduce reconstitution overhead in panels where IGF-1 LR3 is screened alongside other reference peptides. The spray retains the same 83-residue Fmoc-SPPS-synthesized peptide with three intramolecular disulfide bridges as the lyophilized standard, pre-dissolved in a pH-buffered isotonic vehicle.

Synthesis & verification

The active peptide is produced by solid-phase peptide synthesis using Fmoc protecting-group strategy in a U.S.-based ISO 9001:2008 facility, then verified post-formulation for identity (LC-MS), purity (reverse-phase HPLC-UV ≥99.0%), and concentration. Each lot ships with its signed Certificate of Analysis. The COA reading guide walks through every line.

Storage & handling

Pre-reconstituted vials remain stable at 2-8 °C in original packaging for the printed shelf life. Protect from light, avoid freeze-thaw, and store upright. Disulfide bridges are reduction-sensitive — handle away from reducing-agent contamination.

Why BioFusion

Spray-format peptide references can drift if not formulated with internal stability data. BioFusion’s spray vials are verified at formulation and re-verified at release. Batch transparency ledger shows every released lot. Bulk discounts at three+; members save 25% plus complimentary U.S. shipping for 365 days.

For research and laboratory use only. This product is not a drug, food, or cosmetic, and is not intended for diagnostic, therapeutic, or in vivo human use.